Renin-angiotensin system inhibitor use and risk of Parkinson’s disease: a meta-analysis
Acta Neurologica Belgica · 2025
DOI: 10.1007/s13760-024-02560-7 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Acta Neurologica Belgica, 2025. Verfasst von Tian-Xiang Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi University of Chinese Medicine, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Parkinson Disease, Angiotensin-Converting Enzyme Inhibitors, Renin-Angiotensin System, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Laboratory of Polysaccharide Bioactivity Evaluation of Traditional Chinese Medicine of Liaoning Province.
Abstract (Originalsprache)
Background
Hypertension is a recognized risk factor for Parkinson’s disease (PD). The renin-angiotensin system (RAS) inhibitors are widely used to treat hypertension. However, the association of RAS inhibitor use with PD has still been an area of controversy.
Methods
Thus, we conducted a meta-analysis to investigate the relationship between RAS inhibitor use and PD. PUBMED and EMBASE databases were searched for articles published up to Oct 2023. All studies that examined the relationship between RAS inhibitor use and the incidence of PD were included.
Results
Seven studies with total 3,495,218 individuals met our inclusion criteria for this meta-analysis. Overall, RAS inhibitor use was associated with a reduction in PD risk (OR = 0.88, 95%CI = 0.79–0.98) compared with the controls. When restricted the analysis to individuals with RAS inhibitor use indication, RAS inhibitor exposure was also associated with a decreased risk of PD (OR = 0.76, 95%CI = 0.62–0.92). Pooled results of cohort studies also did support a protective role of angiotensin converting enzyme inhibitors (ACEIs) (OR = 0.97, 95%CI = 0.89–1.07) users and angiotensin II receptor blockers (ARBs) (OR = 0.8, 95%CI = 0.63–1.02) in PD.
Conclusion
Overall, RAS inhibitor use as a class is associated with a reduction in PD risk. However, the findings of ACEIs and ARBs may be limited by small sample size. Future well-designed studies considering the classification by inhibitor type, duration, dose, or property of BBB penetration of RAS inhibitors are needed to clarify the contribution of these exposure parameters on the risk of PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi University of Chinese Medicine, Nanning, Guangxi, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang U…
- Guangxi University of Chinese Medicine, Nanning, Guangxi, China. yangzengyangtcm@sina.com.
Förderung
- Key Laboratory of Polysaccharide Bioactivity Evaluation of Traditional Chinese Medicine of Liaoning Province
Zitieren
APA
Xu, T. X., Jiang, H. Y., & Yang, Z. Y. (2025). Renin-angiotensin system inhibitor use and risk of Parkinson’s disease: a meta-analysis. Acta Neurologica Belgica. https://doi.org/10.1007/s13760-024-02560-7
Vancouver
Xu TX, Jiang HY, Yang ZY. Renin-angiotensin system inhibitor use and risk of Parkinson’s disease: a meta-analysis. Acta Neurologica Belgica. 2025. doi:10.1007/s13760-024-02560-7
BibTeX
@article{Xu2025,
author = {Xu, Tian-Xiang and Jiang, Hai-Yin and Yang, Zeng-Yan},
title = {Renin-angiotensin system inhibitor use and risk of Parkinson’s disease: a meta-analysis},
journal = {Acta Neurologica Belgica},
year = {2025},
doi = {10.1007/s13760-024-02560-7}
}
EUVIMED